Mira T. Keddis, M.D.

Location

Contact

SUMMARY

The research of Mayo Clinic nephrologist Mira T. Keddis, M.D., focuses on improving cardiovascular evaluation and management of kidney transplant candidates and recipients and evaluating these patients' access to care and clinical outcomes. In addition, she has a special interest in health care delivery in the Native American population before and after kidney transplant.

Focus areas

• Cardiovascular risk assessment of kidney transplant candidates. Dr. Keddis works collaboratively with Mayo Clinic's Division of Cardiovascular Diseases to evaluate cost-effective models of cardiovascular screening for patients presenting for kidney transplant evaluation.
• Cardiac biomarkers in the care and outcomes in kidney transplant patients. Dr. Keddis' interest in this area includes identifying clinical and laboratory determinants of cardiac troponin T and sST2 biomarkers in kidney transplant candidates and individuals post-transplant and elucidating mechanisms behind variation in these variables. The goal is to understand how these variables can stratify patients at risk of adverse cardiovascular events and implement practice changes to improve overall cardiovascular health of these patients.
• Health disparities in access to care and outcomes in the Native American population. Dr. Keddis' interest in this area includes evaluation of factors that impact duration of transplant evaluation process, transplant candidacy and time to transplantation in the Native American population. The goal is to analyze post-transplant cardiovascular, infectious and malignancy complications in the Native American kidney transplant cohort. Successful understanding of factors that impact access to kidney transplant and transplant outcomes will help in the conceptualization of a new framework for transplant care for Native American individuals.
• Utility of cystatin C for assessment of graft function and clinical outcome in kidney transplant patients. Dr. Keddis' research interests include the study of the biomarker cystatin C, its role in assessment of graft function and its association with adverse outcome in kidney transplant patients.

Significance to patient care

Cardiovascular disease is one of the most common complications in patients with kidney disease before and after kidney transplant. The current process of assessing patients for cardiovascular risk is challenging. By understanding how different imaging modalities and cardiac biomarkers can stratify the risk of cardiovascular disease in these patients, Dr. Keddis hopes to improve the process of risk stratification prior to kidney transplant and to implement cardioprotective measures that can decrease patient risk after kidney transplant.

Professional highlights

• Director of education, Center for Individualized Medicine, Mayo Clinic, 2022-present